The impact of residual symptoms on relapse and quality of life among Thai depressive patients

2017 ◽  
Vol 41 (S1) ◽  
pp. S326-S327
Author(s):  
T. Tantrarungroj ◽  
D. Nakawiro ◽  
T. Wongpakaran ◽  
N. Wongpakaran ◽  
P. Bookkamana ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Regression Analysis ◽  
Depressive Disorder ◽  
Depressive Disorders ◽  
Rating Scale ◽  
Residual Symptom ◽  
Residual Symptoms ◽  
Symptoms Of Depression ◽  
The Impact

IntroductionResidual symptoms of depressive disorder are major predictors of relapse of depression and lower quality of life. This study aims to investigate the prevalence of residual symptoms, relapse rates and quality of life among Thai patients with depressive disorders.MethodsHamilton Rating Scale for Depression (HAM-D) and EQ-5D were used to measure the symptoms of depression and quality of life, respectively. Prevalence of residual symptoms of depression was collected. Regression analysis was administered to predict relapse and patients’ quality of life at the 6 months post-baseline.ResultsTwo hundred and twenty-four depressive disorder patients were recruited. Most of patients (93.3%) had at least one residual symptom, and the most common residual symptom was anxiety symptoms (76.3%; 95% CI, 0.71 to 0.82). After 3 months post-baseline, 114 patients (50.9%) were in remission and within 6 months, 44 of them (38.6%) relapsed. Regression analysis showed that residual insomnia symptoms were significantly associated with these relapse cases (OR = 5.290, 95% CI, 1.42 to 19.76). Regarding quality of life, residual core mood and insomnia significantly predicted the EQ5D scores at 6 months post-baseline (B = −2.670, 95% CI, −181 to −.027, and B = −3.109, 95% CI, −172 to −.038, respectively).DiscussionResidual symptoms are common in patients receiving treatment for depressive disorder and were found to be associated with relapses and quality of life. Clinicians need to be aware of these residual symptoms when carrying out follow-up treatment in patients with depressive disorders, so that prompt action can be taken to mitigate the risk of relapse.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals The Influence of Antiarrhythmic Device Intervention on Biopsychosocial Functioning and Anxiety in Patients with an Implanted Cardioverter Defibrillator

Medicina ◽  
2021 ◽  
Vol 57 (2) ◽  
pp. 113
Author(s):  
Olimpia Karczewska ◽  
Agnieszka Młynarska
Keyword(s):  
Quality Of Life ◽  
Psychosocial Functioning ◽  
Depressive Disorders ◽  
Icd Implantation ◽  
Cardioverter Defibrillator ◽  
Symptoms Of Depression ◽  
Two Stages ◽  
Number Of Discharges ◽  
The Impact

Background and objectives: The aim of the study was to assess the impact of cardioverter-defibrillator interventions on the psychosocial functioning of a patient and the occurrence of concerns related to ICD. Materials and Methods: The conducted study was a prospective and observational study that included 158 patients. The study was conducted in two stages: I before ICD implantation and II a follow-up visit six months after the ICD implantation. Standardized questionnaires were used in both stages. Results: In the first six months, a cardioverter-defibrillator discharge occurred in 28 participants, which constituted 17.72% of the study group. The number of ICD discharges positively correlated to insomnia, symptoms of anxiety, symptoms of depression, more discharges, more severe insomnia, anxiety and depression. There was also a negative correlation between the number of discharges and the degree of disease acceptance and in the quality of life domains: somatic, mental, social and environmental. The more discharges, the worse the disease acceptance and assessment of the quality of life. Conclusions: Individuals who experienced discharges assessed their quality of life as worse in all aspects (perception of the quality of life, own health, physical, mental, social and environmental domains), experienced anxiety and depressive disorders more often, were characterized by a worse functioning in a chronic disease, experienced insomnia more often and reported more concerns related to ICD implantation.

Longitudinal Trends in Quality of Life and Physical Function in Frail Older Dialysis Patients: A Comparison of Assisted Peritoneal Dialysis and In-Center Hemodialysis

2019 ◽  
Vol 39 (2) ◽  
pp. 112-118 ◽  
Author(s):  
Osasuyi Iyasere ◽  
Edwina Brown ◽  
Fabiana Gordon ◽  
Helen Collinson ◽  
Richard Fielding ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Peritoneal Dialysis ◽  
Mixed Model ◽  
Rating Scale ◽  
Depression Scale ◽  
Dialysis Patients ◽  
The Impact ◽  
Assisted Peritoneal Dialysis

Background In-center hemodialysis (HD) has been the standard treatment for older dialysis patients, but reports suggest an associated decline in physical and cognitive function. Cross-sectional data suggest that assisted peritoneal dialysis (aPD), an alternative treatment, is associated with quality of life (QoL) outcomes that are comparable to in-center HD. We compared longitudinal changes in QoL between modalities. Methods We enrolled 106 aPD patients, matched with 100 HD patients from 20 renal centers in England and Northern Ireland. Patients were assessed quarterly for 2 years using the Hospital Anxiety and Depression Scale (HADS), SF-12 physical and mental scores, symptom score, Illness Intrusiveness Rating Scale (IIRS), Barthel's score, and the Renal Treatment Satisfaction Questionnaire (RTSQ). Mixed model analysis was used to assess the impact of dialysis modality on these outcomes during follow-up. P values were adjusted for multiple significance testing. Results Multivariate analysis showed no difference in any of the outcome measures between aPD and HD. Longitudinal trends in outcomes were also not significantly different. Higher age at baseline was associated with lower IIRS and RTSQ scores during follow-up. One-hundred and twenty-five (60.6%) patients dropped out of the study: 59 (28.6%) died, 61 (29.6%) withdrew during follow-up, and 5 (2.5%) were transplanted. Conclusions Quality of life outcomes in frail older aPD patients were equivalent to those receiving in-center HD. Assisted PD is thus a valid alternative to HD for older people with end-stage kidney disease (ESKD) wishing to dialyze at home.

scholarly journals Tourism Impacts on the Quality of Life in Hong Kong

2017 ◽  
Vol 9 (3) ◽  
pp. 103 ◽  
Author(s):  
Huijun Yang ◽  
Grace Chan Suk Chan ◽  
Wenjie Li
Keyword(s):  
Quality Of Life ◽  
Regression Analysis ◽  
Hong Kong ◽  
Important Determinant ◽  
Positive Influence ◽  
Tourism Impacts ◽  
Five Dimensions ◽  
Local Residents ◽  
The Impact

This study aims to examine the impact of specific dimensions of tourism impacts on Hong Kong residents’ satisfaction with the quality of life. While factor analysis is used to explore the attributes and dimensions of tourism impacts, multiple regression analysis is employed to determine the tourism impacts on residents’ satisfaction with the quality of life. It is evident from the results that two of the five dimensions of tourism impacts have positive influence on residents’ satisfaction. Image and infrastructure are found to be the important determinant factors in explaining the satisfaction. The impacts of environment, economy, and services in affecting satisfaction seem to be insignificant. In order to maintain tourism sustainability in Hong Kong, the local residents’ perception should be taken into consideration. Recommendations are provided to achieve mutual benefits and harmonious development. 

Suicidal ideation and other persisting symptoms after CBT or antidepressant medication treatment for major depressive disorder

2018 ◽  
Vol 49 (11) ◽  
pp. 1869-1878 ◽  
Author(s):  
Boadie W. Dunlop ◽  
Philip E. Polychroniou ◽  
Jeffrey J. Rakofsky ◽  
Charles B. Nemeroff ◽  
W. Edward Craighead ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Suicidal Ideation ◽  
Depressive Disorder ◽  
Rating Scale ◽  
Antidepressant Medication ◽  
Major Depressive ◽  
Residual Symptom ◽  
Residual Symptoms ◽  
Antidepressant Medications ◽  
Item Scores

AbstractBackgroundPersisting symptoms after treatment for major depressive disorder (MDD) contribute to ongoing impairment and relapse risk. Whether cognitive behavior therapy (CBT) or antidepressant medications result in different profiles of residual symptoms after treatment is largely unknown.MethodsThree hundred fifteen adults with MDD randomized to treatment with either CBT or antidepressant medication in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study were analyzed for the frequency of residual symptoms using the Montgomery Asberg Depression Rating Scale (MADRS) item scores at the end of the 12-week treatment period. Separate comparisons were made for treatment responders and non-responders.ResultsAmong treatment completers (n= 250) who responded to CBT or antidepressant medication, there were no significant differences in the persistence of residual MADRS symptoms. However, non-responders treated with medication were significantly less likely to endorse suicidal ideation (SI) at week 12 compared with those treated with CBT (non-responders to medication: 0/54, 0%, non-responders to CBT: 8/30, 26.7%;p= .001). Among patients who terminated the trial early (n= 65), residual MADRS item scores did not significantly differ between the CBT- and medication-treated groups.ConclusionsDepressed adults who respond to CBT or antidepressant medication have similar residual symptom profiles. Antidepressant medications reduce SI, even among patients for whom the medication provides little overall benefit.

Depressive and Bipolar Disorders

2017 ◽  
Author(s):  
Antoine Douaihy ◽  
Matthew Conlon ◽  
Maria Ferrara
Keyword(s):  
Quality Of Life ◽  
Antiretroviral Therapy ◽  
Sexual Behaviors ◽  
Depressive Disorders ◽  
Bipolar Disorders ◽  
Poor Quality ◽  
Persons Living With Hiv ◽  
The Impact ◽  
Hiv Aids

Depressive disorders are highly prevalent among persons living with HIV/AIDS. Depressive disorders significantly negatively affects adherence to antiretroviral therapy and HIV viral suppression and is associated with poor quality of life and major impairment in overall functioning. This chapter reviews the prevalence, risk factors, assessment and diagnosis of depressive and bipolar disorders. It also examines the impact of depression on sexual behaviors, adherence to antiretroviral therapy, quality of life, and mortality. This chapter also includes a comprehensive discussion of treatment approaches and considerations for HIV-infected individuals with depressive disorders. Furthermore, it reviews the bipolar disorder spectrum in HIV/AIDS as well as other psychiatric disorders co-occurring with depressive disorders.

Influence of art therapy in complex treatment on the quality of remission in patients with recurrent depressive disorder

2016 ◽  
Vol 33 (S1) ◽  
pp. S559-S559
Author(s):  
V. Korostiy ◽  
S. Hmain
Keyword(s):  
Quality Of Life ◽  
Depressive Disorder ◽  
Art Therapy ◽  
Combined Treatment ◽  
Control Group ◽  
Complex Treatment ◽  
Residual Symptoms ◽  
Remission Period ◽  
Competing Interest

IntroductionAccording to studies done in recent years regarding the treatment of patients with recurrent depressive disorder, a shift of interest from studies evaluating the effectiveness of therapy to the study of remission is seen. According to the literature, complete remission occurs in only 40–50% of patients, in other cases there is residual symptoms.AimsEvaluating the effectiveness of art therapy in treatment in patients with recurrent depressive disorder on the quality of remission.MethodsThe study involved 135 patients: 60 male and 75 female patients aged from 18 to 30 years old. The main group of patients apart the combined treatment also participated in group art therapy with the use of drawing techniques, while the control group – statutory standard therapy. We used clinical, psychopathological, psychodiagnostic and statistical methods.ResultsThe results of the effectiveness of art therapy in complex treatment in patients with recurrent depressive disorder is detected primarily in reducing of the level of anxiety at the early stages of treatment, as well as in reducing of the severity of anhedonia and improving the quality of life in remission period.ConclusionThese results support the use of art therapy in treatment in patients with recurrent depressive disorder during period of active treatment, and after achieving clinical remission contributes to achieving and maintaining high-quality and stable remission with full restoration of quality of life and social functioning.Disclosure of interestThe authors have not supplied their declaration of competing interest.

The Use of Art Therapy in Complex Treatment on the Quality of Remission in Patients with Melancholy in Major Depressive Disorder

2017 ◽  
Vol 41 (S1) ◽  
pp. s777-s777 ◽  
Author(s):  
H. Kozhyna ◽  
V. Korostiy ◽  
S. Hmain ◽  
V. Mykhaylov
Keyword(s):  
Quality Of Life ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Art Therapy ◽  
Depressive Disorders ◽  
Combined Treatment ◽  
Control Group ◽  
Complex Treatment ◽  
Major Depressive

IntroductionAccording to studies done in recent years regarding the treatment of patients with melancholy in major depressive disorder, a shift of interest from studies evaluating the effectiveness of therapy to the study of remission is seen. Despite significant progress in the development of pharmacotherapy of depressive disorders, difficulty in achieving rapid reduction in depressive symptoms and stable remission in patients with melancholic depression necessitated the search for new approaches to the treatment of this pathology.AimsEvaluating the effectiveness of art therapy in treatment in patients with melancholy in major depressive disorder on the quality of remission.MethodsThe study involved 135 patients – 60 male and 75 female patients aged from 18 to 30 years old. The main group of patients apart the combined treatment also participated in group art therapy with the use of drawing techniques, while the control group – statutory standard therapy.ResultsThe results of the use of art therapy in complex treatment in patients with major depressive disorder is detected primarily in reducing of the level of anxiety at the early stages of treatment (60% of patients have noticed decreasing of melancholic state), as well as improving the quality of life in remission period.ConclusionThese results support the use of art therapy in treatment in patients with melancholy in major depressive disorder during period of active treatment, and after achieving clinical remission contributes to achieving and maintaining high-quality and stable remission with full restoration of quality of life and social functioning.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Quality of life in schizophrenia and bipolar disorder: The impact of symptomatic remission and resilience

2017 ◽  
Vol 46 ◽  
pp. 42-47 ◽  
Author(s):  
A. Hofer ◽  
Y. Mizuno ◽  
F. Wartelsteiner ◽  
W. Wolfgang Fleischhacker ◽  
B. Frajo-Apor ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Rating Scale ◽  
Young Mania ◽  
Cross Sectional ◽  
Control Subjects ◽  
The Difference ◽  
Lower Hrqol ◽  
Symptomatic Remission ◽  
The Impact

AbstractBackground:Health-related quality of life (HRQOL) is significantly affected in individuals with schizophrenia or bipolar I disorder (BD-I). The current study investigated whether symptomatic remission and resilience might differently impact HRQOL in these patients.Methods:Fifty-two patients with schizophrenia and 60 patients suffering from BD-I from outpatient mental health services as well as 77 healthy control subjects from the general community were included into a cross-sectional study. HRQOL and resilience were assessed using the WHOQOL-BREF and the Resilience Scale. In patients, psychopathology was quantified by the Positive and Negative Syndrome Scale or the Montgomery Asberg Depression Rating Scale and the Young Mania Rating Scale, respectively.Results:Notably, both patient groups showed lower HRQOL and resilience compared to control subjects, non-remitted patients indicated lower HRQOL than remitted ones. The effect of remission on HRQOL was significantly larger in patients with BD-I than in those with schizophrenia but did not explain the difference in HRQOL between groups. Resilience predicted HRQOL in all three groups. When accounting for the effect of resilience among remitted patients, only the difference in HRQOL between schizophrenia patients and control subjects was significant.Conclusion:These findings demonstrate the impact of symptomatic remission and resilience on HRQOL of both patients suffering from schizophrenia and BD-I and indicate that these factors are especially relevant for HRQOL of patients with BD-I.

Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial

2017 ◽  
Vol 51 (8) ◽  
pp. 829-840 ◽  
Author(s):  
Olivia M Dean ◽  
Buranee Kanchanatawan ◽  
Melanie Ashton ◽  
Mohammadreza Mohebbi ◽  
Chee Hong Ng ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Major Depressive Disorder ◽  
Confidence Interval ◽  
Depressive Disorder ◽  
Clinical Global Impression ◽  
Effect Size ◽  
Rating Scale ◽  
Controlled Trial ◽  
Major Depressive

Objective: Conventional antidepressant treatments result in symptom remission in 30% of those treated for major depressive disorder, raising the need for effective adjunctive therapies. Inflammation has an established role in the pathophysiology of major depressive disorder, and minocycline has been shown to modify the immune-inflammatory processes and also reduce oxidative stress and promote neuronal growth. This double-blind, randomised, placebo-controlled trial examined adjunctive minocycline (200 mg/day, in addition to treatment as usual) for major depressive disorder. This double-blind, randomised, placebo-controlled trial investigated 200 mg/day adjunctive minocycline (in addition to treatment as usual) for major depressive disorder. Methods: A total of 71 adults with major depressive disorder ( Diagnostic and Statistical Manual of Mental Disorders–Fourth Edition) were randomised to this 12-week trial. Outcome measures included the Montgomery–Asberg Depression Rating Scale (primary outcome), Clinical Global Impression–Improvement and Clinical Global Impression–Severity, Hamilton Anxiety Rating Scale, Quality of Life Enjoyment and Satisfaction Questionnaire, Social and Occupational Functioning Scale and the Range of Impaired Functioning Tool. The study was registered on the Australian and New Zealand Clinical Trials Register: www.anzctr.org.au , #ACTRN12612000283875. Results: Based on mixed-methods repeated measures analysis of variance at week 12, there was no significant difference in Montgomery–Asberg Depression Rating Scale scores between groups. However, there were significant differences, favouring the minocycline group at week 12 for Clinical Global Impression–Improvement score – effect size (95% confidence interval) = −0.62 [−1.8, −0.3], p = 0.02; Quality of Life Enjoyment and Satisfaction Questionnaire score – effect size (confidence interval) = −0.12 [0.0, 0.2], p < 0.001; and Social and Occupational Functioning Scale and the Range of Impaired Functioning Tool score – 0.79 [−4.5, −1.4], p < 0.001. These effects remained at follow-up (week 16), and Patient Global Impression also became significant, effect size (confidence interval) = 0.57 [−1.7, −0.4], p = 0.017. Conclusion: While the primary outcome was not significant, the improvements in other comprehensive clinical measures suggest that minocycline may be a useful adjunct to improve global experience, functioning and quality of life in people with major depressive disorder. Further studies are warranted to confirm the potential of this accessible agent to optimise treatment outcomes.

Pruritus and Malodour in Patients with Hidradenitis Suppurativa: Impact on Quality of Life and Clinical Features Associated with Symptom Severity

Dermatology ◽  
2019 ◽  
Vol 236 (1) ◽  
pp. 59-65 ◽  
Author(s):  
Alejandro Molina-Leyva ◽  
Carlos Cuenca-Barrales
Keyword(s):  
Quality Of Life ◽  
Clinical Features ◽  
Hidradenitis Suppurativa ◽  
Rating Scale ◽  
Life Quality ◽  
Numeric Rating Scale ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
The Impact

Background: Patients with hidradenitis suppurativa (HS) suffer from symptoms such as pruritus and malodour which can significantly impair their quality of life. Objectives: (1) To analyse the impact of pruritus and malodour on the quality of life of patients with HS and (2) to explore the potential association between clinical features and the severity of these symptoms. Patients and Methods: This is a cross-sectional study. The Numeric Rating Scale (NRS) was used to assess pruritus and malodour. Quality of life was assessed by means of the Dermatology Life Quality Index (DLQI). Results: Two hundred and thirty-three patients were included in the study. Both pruritus and malodour positively correlated with worse quality of life (p < 0.05). Pruritus intensity was associated with the number of regions affected by HS, female sex, the intensity of suppuration, and the presence of comorbid Crohn’s disease. Statin use was associated with lower levels of pruritus. Malodour intensity was associated with higher body mass index, disease duration, the number of regions affected, Hurley stage, and intensity of suppuration. Conclusions: The results of our study show that pruritus and malodour are key symptoms in patients with HS which have a great impact on their quality of life. We have identified clinical features potentially associated with the intensity of these symptoms which could be useful to identify higher-risk patients and may influence treatment decisions.

Sign in / Sign up

Export Citation Format

Share Document